Paysign, Inc. (PAYS) Earnings Call Transcript
May 12, 2026
Earnings Call Speaker Segments
Thanks, Kevin. Hi everybody, good afternoon, and I appreciate you being with us for the Paysign First Quarter 2026 Earnings Call. My name is Mark Newcomer, and I serve as President and Chief Executive Officer. With me is Jeff Baker, who holds the Chief Financial Officer role. We also have Matt Turner, President of Patient Affordability, and Matt Lanford, our Chief Payments Officer, on the line; both will be around for Q&A once we finish our prepared remarks. Earlier today we released our first quarter financial results, and they represented the best opening to any year in the company's history. Revenue rose 50.8% to $28 million, above the top end of the guidance we gave back in March. Net income climbed 110% to $5.4 million, while adjusted EBITDA was up 113% to $10.6 million. What stands out most is that operating margins improved 1,040 basis points, or 10.4%, versus a year ago, which shows the operating leverage built into our business as we grow across health care and financial ecosystems. Growth remained strong in patient affordability during the first quarter. That segment's revenue was up 82% year-over-year, reaching $15.7 million, and claim volume came in roughly 49% above Q1 2025, fueled by a mix of newly launched programs over the last year, organic expansion inside existing programs, and the ongoing ramp of our biggest pharmaceutical clients. As we anticipated, this rate sits on a bigger, more mature revenue base than it did a year ago; during Q1 by itself, patient affordability brought in almost as much revenue as it produced across the first half of 2025. In the quarter, our patient affordability business provided over $540 million in financial assistance to patients, a significant increase from about $320 million in the first quarter of last year; that gain reflects both the larger number of patients we serve and the growing role our business plays in supporting access to high-cost branded therapies. Our dynamic business rules technology keeps delivering substantial economic value to our pharmaceutical clients and to the patients who depend on their therapies, which demonstrates both the scale our platform now operates at and the differentiated value our technology provides in helping manufacturers navigate co-pay maximizer and accumulator programs; we launched 4 new programs during the first quarter, bringing total active programs to 135. As is usual for the industry, Q1 is the period of the year with the most operational constraints, since manufacturers, payers and pharmacy partners are working through plan year transitions, formulary changes and deductible resets. Even so, our pipeline remains robust, and we expect to surpass the 55 net program additions we launched in 2025. The strength of that pipeline reflects the trust pharmaceutical manufacturers continue to place in Paysign as a partner in helping patients access and afford the therapies they need. All together, the growth we are seeing in program count, claim volume and benefit dollars deployed reinforces both the scalability of our platform and the durability of demand for our solutions. Last month, we attended the Assembia Specialty Pharmacy Summit, ASX 26 in Las Vegas. Assembia stands as the premier yearly conference for the specialty pharmaceutical sector, and it reliably ranks among the highest-yield events for building pipeline on our schedule. This is the venue where key decision-makers from drug makers, specialty pharmacies, hub providers, and payer partners all convene under one roof. The discussions held across those 3 days played a role in shaping our commercial road map for the rest of the year. ASX 26 followed that same pattern. Over 3 days we held in excess of 50 meetings and signed new business right there on site. The range and depth of those discussions, paired with the deals we locked in live, bolster our confidence in both the demand picture and the durability of our pipeline as we move through the rest of 2026. Now turning to our business in plasma donor compensation. Plasma brought in $11.7 million of revenue during the first quarter, which represents a 25% gain compared with $9.4 million in Q1 2025. Our plasma operation also continues to be a robust generator of cash, enabling investments into areas of high opportunity. Looking forward, we anticipate ongoing revenue growth as current centers fill spare capacity, a large portion of which has been freed up thanks to recent breakthroughs in plasmapheresis hardware, delivering major efficiencies to the plasmapheresis process. Reacting to that added capacity, a number of our bigger collectors have merged operations, shutting down certain underperforming centers. In the past, such closures barely moved our results because donors usually shift to nearby centers, and we anticipate that same dynamic will unfold after our clients shut 19 centers in early May; we finished the quarter with 573 centers, which is 89 more than a year earlier, yet 22 fewer than at the close of 2025, since several weak centers were either sold off to collectors who don't use our services or were closed. Once again, we don't think these shutdowns will hurt our growth outlook, and we keep going after the remaining plasma collection companies that aren't yet our customers. During late April, we served as sponsor of the International Plasma Protein Congress in Milan, Italy, where we met with plasma collectors, device makers, and industry players from the U.S., Europe, and Asia. That conference drove real momentum for our Software-as-a-Service suite of solutions, encompassing conversations with plasma collection companies spanning all 3 regions and with plasmapheresis device manufacturers about direct integration into our platform. When our software directly integrates with plasmapheresis devices, it removes manual steps that could otherwise bring human error into the collection process. It also makes implementation smoother and lowers friction for collection centers as they move onto our platform, delivering a clear operational advantage. Outside the U.S., we still see Europe and Asia as major long-term opportunities for our SaaS solutions throughout the blood and plasma collection industries; to wrap up, the first quarter represented an excellent beginning to 2026 and a significant inflection point for Paysign. We posted record results throughout the business and, more crucially, confirmed the strategic direction we've established, purpose-built platforms rooted in deep industry expertise, scaling with discipline as we expand. Thanks to powerful momentum around what patients can afford, a solid pipeline, plus widening chances inside health care and outside it too, we're set up nicely to deliver lasting growth and build value over the long term for shareholders, customers and the people we serve in the end; so with that, I'll hand things over to Jeff, who can share more specifics about how we did financially in the first quarter.
Mark, thank you, and hello everyone on this afternoon's call. The first-quarter numbers, as Mark mentioned, demonstrate that our business keeps building momentum, that our patient affordability platform is delivering a growing financial impact, and that we have now crossed an inflection point with respect to operating leverage. Total revenues for Q1 came in at $28 million, an increase of 50.8% over the same period last year. Turning to our pharma segment, revenue there hit $15.7 million, up 81.9% from the prior-year period, driven by 45 net pharma patient affordability programs launched during the last 12 months, together with comparable growth in monthly management fees, setup fees, claim processing fees, and other billable offerings such as dynamic business rules and customer service contact center support. Compared with the first quarter of 2025, processed claims were up about 49%. And during this quarter, Pharma overtook plasma to become our largest source of revenue for the first time ever — a milestone that reflects both the strategy we've been executing and how patient affordability is becoming more important to our business. Plasma brought in $11.7 million, a 24.9% increase over the prior year. Revenue per center averaged $6,671 per month, up from $6,517, and for the first time since the inventory correction that began hitting the industry in 2024, the average number of loads per center increased year over year. To pick up on what Mark said, we finished the quarter with 573 centers, which came in below the 589 we had guided to. The reason is that a single customer informed us it had divested all of its locations to a competing provider. Those centers accounted for about $650,000 in 2025 revenue and generated an average of just under $3,500 each month, a figure that sits below our company-wide average of $6,671. On gross profit margin, we expanded to 65% from 62.9% in Q1 2025, reflecting a larger contribution from Pharma revenue, which carries stronger gross margins than our plasma segment. Our cost of revenues increased 42.2%, driven primarily by higher call center support costs associated with expansion in Plasma as well as Pharma, along with increased processing and commission expenses — and every one of those areas grew well below the 50.8% revenue increase, which demonstrates the operating leverage our business contains. Total operating expenses came in at $11.6 million, representing a 25.5% increase over the $9.2 million recorded in the first quarter of 2025, again significantly trailing our rate of revenue growth. Selling, general and administrative expenses were up 20.5%, reaching $8.9 million, and that number includes $1.3 million in stock-based compensation. Depreciation and amortization increased by $835,000, largely reflecting amortization of intangible assets connected to the Gamma acquisition as well as capitalization of new software development costs. A major highlight this quarter was the combination of solid top-line expansion and strong operating leverage. Our operating margin climbed to 23.8%, up from 13.4% during Q1 of 2025 — that's a gain of more than 1,000 basis points. Put another way, roughly $9.4 million of additional revenue translated into $4.2 million of operating income. There were a few other things worth noting this quarter: pre-tax income increased to $7.5 million, compared with $3.3 million in the first quarter of 2025. Our income tax provision came to $2 million, resulting in an effective tax rate of 27.2%, as opposed to 20.5% in Q1 of 2025. That elevated rate stems from adjustments to discrete items, driven largely by how our share price on March 31, 2026 compared with the level it sat at during the same stretch one year before, and it reduced the tax benefit we booked from stock-based compensation versus the earlier year's period. For the quarter, net income reached $5.4 million, equal to $0.09 per fully diluted share, an increase over the $2.6 million, or $0.05 per fully diluted share, recorded in the first quarter of 2025. Adjusted EBITDA, a measure that strips out stock-based compensation and that management relies on to gauge core operating performance, climbed 113.4% to $10.6 million, or $0.17 per fully diluted share, compared with $5 million, or $0.09 per fully diluted share, in the first quarter of 2025. On an adjusted EBITDA basis, our margin expanded to 37.8%, up from 26.7% during the same period last year. For per-share calculations, the fully diluted count came to $61 million, versus $55.1 million a year earlier. Unrestricted cash at quarter's end totaled $20.5 million, and we carried no bank debt. Restricted cash increased by $15 million, reaching $159 million, primarily from deposits tied to customer programs serving our Plasma and Pharma clients, along with growth in funds held on card. Now, moving to our outlook: across every line of the income statement, first quarter results exceeded our guidance. Revenue reached $28 million, surpassing the top end of our $27 million to $27.5 million range. Our operating margin came in at 23.8%, which was better than the 20% to 22% range we had guided to, while net margin reached 19.4%, also ahead of our 17% to 19% guidance. With such a solid beginning to the year, our confidence keeps growing that we can hit the top end of the ranges we laid out for 2026. For the full year, revenue is still projected at $106.5 million to $110.5 million, which would be 30% to 35% growth compared with last year, and gross profit margins should fall between 60% and 62%. We anticipate net income of $13 million to $16 million, equal to $0.21 to $0.26 per diluted share, while adjusted EBITDA should land between $30 million and $33 million, or $0.49 to $0.53 per diluted share. Right now, we're sitting at 141 patient affordability programs that are active, and when the quarter wraps up, we anticipate having somewhere between 147 and 150 of them running. On the plasma side, our count of active centers should drop into the 555 to 560 range, since a customer shut down 19 locations in May that weren't performing well. Just like we've seen before, we don't anticipate these closures moving the financial needle, because we figure the cardholders tied to those weaker centers will simply move their business to other locations. One thing to keep in mind: both of our primary businesses follow seasonal patterns. In pharma, revenue tends to reach its high point during Q1, when claims for patient affordability hit their peak alongside annual insurance deductible resets, before settling down over the rest of the year. If you look at plasma revenue instead, the weakest period is usually Q1, then it climbs across the rest of the year once donor activity settles back down after tax refund season. We expect these seasonal patterns, and they are completely baked into the guidance for the full year. Taking everything together, our Q1 performance confirms the financial framework we presented in March, and the operating leverage coming through makes us confident that we can keep meeting the forecast we set out for 2026. With that said, I'll hand the call back to Kevin so we can move to questions and answers.
Nice quarter — congratulations on that. Mark, early on in this call you mentioned expecting to beat the 55 net program adds you had in 2025. To start with, what's behind that confidence in the pipeline strength? Is there some one-off event you're looking at? Or is it mainly — and this may be Part B — is it mainly new or existing customers that add to things in the back half of the year?
Matt Turner here. If you looked at how the pipeline stands at this moment, there's a fairly healthy blend, roughly 50 to 50 based on the program count we're discussing now, the one going past 55, where one half will be completely new clients and the other half will be growth within clients we already have. I don't think there's any — there isn't a single moment that's an inflection point. On the last call, we discussed what inning we were in. And I think this demonstrates that what we built on in the first inning, right, is paying off now. So we have a bigger client base. So we'll keep seeing new programs from those clients, and then selling never stops. So we're always working to bring new clients onto the platform.
Understood. So, assuming my figures are off, that would suggest roughly 190 programs leaving in 2026. From a capacity angle, do you feel you've got the additional room? What would it take, I suppose, to bring those programs on completely?
I don't believe anything more is required. What I mean is, we'll keep bringing on staff to back the business on the account management side. When it comes to IT, our systems are sturdy and nicely set up to manage the expansion we're seeing this year and whatever years lie ahead. So we've designed systems with high availability and high demand. Every partner we work with in this area is accustomed to bigger claim volumes along these lines. So we're sure that everything necessary is already there for us to keep scaling the growth annually.
Understood. And then perhaps we could briefly address some of the guidance commentary. I realize you both indicated that you anticipate revenue to be approximately flat. When we look at the plasma centers, clearly you're forecasting a decrease in Q2 here. If I'm understanding that correctly, it suggests a fairly substantial ramp in the back half for plasma revenue?
No. Plasma revenue ought to rise sequentially and keep expanding through the remainder of the year. So the centers we identified for the quarter that got sold were garbage centers, frankly speaking, and those fell short of our corporate averages. And then regarding the centers that were consolidated or shut down, that company has other centers close to the ones they closed. So those cardholders are simply going to migrate over; but we — there are some — the — I made some remarks to give you a sort of advance notice. I mean we saw average loads per center increase for the first time since 2024 on a year-over-year basis. So we discussed the inventory overhang that we dealt with all throughout 2025, and we're seeing early signs that we've moved past that. Now what you're observing is some plasma companies attempting to become more efficient; they're shutting underperforming centers. We've crunched the numbers on those centers. They ought to have closed them quite a while ago, honestly. But the fact is we've been through this before nearly every year, and it doesn't affect the numbers; so we expect plasma to keep growing throughout the year and maintain that 50 to 50 mix right now as we see it, subject to change as we move forward.
Jeff, there are quite a few figures being mentioned in this discussion. I'd like to confirm that I understand it properly. According to what your press release states, there are currently 135 pharma programs, is that right?
That's not correct. Based on the press release covering the quarter, when that quarter ended, we had 135 programs. Right now, as I'm speaking at 5:20 today, the count of active programs stands at 141. Before the second quarter wraps up, as I've already communicated to you, the number of active programs will fall somewhere from 147 to 150.
All right, that clears up my confusion. Then regarding plasma, you had 573, and the range you'll land in is 550 to 560.
Correct; at the close of the quarter we stood at 573. After that, a customer informed us they'd be closing 19 centers on May 5. I also mentioned that we anticipate finishing the second quarter somewhere in the 555 to 560 range, since additional new centers are coming online through our pipeline.
All right, that clears things up. I simply want to confirm I understood it correctly. So Mark, you mentioned briefly your plasma platform and the way you're bringing it into these providers. First, what benefits in terms of competition does an organization gain by plugging into that platform? How does it function alongside the application you've created? And after that, do any other companies exist that offer a platform matching your technical abilities?
When we consider the full ecosystem we've assembled — the platform including its different app modules, the CRM, the qualitative analysis, plus all the rest — we don't observe any comparable companies anywhere who have created something resembling ours; this is somewhat what we've heard back, that having software components able to talk to each other and draw from each other is unquestionably an improvement over what people previously possessed. So from the viewpoint of a plasma center, it means reduced friction compared to their present setup and lets a center enjoy not merely reduced friction but simply greater ease of use and the way they deal with donors, with engagement throughout. So essentially it comes down to reduced friction along with simply superior capabilities.
Then just a few more items, and I'll step away. One of the people — I've lost track of which name this belongs to — mentioned the pharma programs, saying roughly half consist of takeaways and the other half are new programs. Does that roughly describe how your new wins are shaping up?
Well, there's a distinction between a transition and a launch product, correct? So those two things differ quite a bit. What I mean is — but his questions concerned new clients as opposed to existing clients, correct? We treat a client as a manufacturer, and that manufacturer might have 30 drugs. So suppose they gave us 5 last year, and this year they bring on another 2 or 3 programs, correct? Then we'd call those existing client additions; that would be distinct from transitions versus launches. At this moment I don't have a fixed figure I can give you along the lines of, hey, this is how we expect that to line up, because the pipeline is the pipeline, correct? It's a living, breathing thing. My expectation is that this year we'll see more transitions than we see new product launches. That said, that's where things stand right now in May. Ultimately, though, the result will remain unchanged, since we're focused on reaching our guidance targets.
All right. Then only one more thing, very fast, and I'll let someone else take a turn. It seems you discussed how additional revenue turns into additional operating income. My approach to measuring it is different. What I'm examining is incremental adjusted EBITDA conversion; and Jeff, during the quarter that appeared to be near 60%; and then when I look at your guidance ahead, just based on my figures, across the following 3 quarters it falls off quite a bit. So is this simply a result of mix, since you'll have more plasma revenue in the mix compared with patient affordability?
That's right.
That's the whole point. Nothing is getting more money behind it except the usual expansion and that kind of thing?
Correct. What I'd say is everything is already reflected in the guidance. So when you scroll down and revisit every piece of guidance we provided in that table within the press release, there are no revisions; thus it's simply a mix shift as the year progresses. Patient affordability ought to tick down somewhat since our claims decline, exactly as happened a year ago, balanced out by additional programs we bring on. After that, plasma is going to keep expanding, ought to keep expanding across the year, exactly as it has each year since we entered this business. So the seasonal elements stay the same, yet that is what — that will clearly produce a slight movement on the margin front. The remark we're offering regarding margin for those purists who insist on examining operating margin, factoring in depreciation, amortization, stock comp, that's exactly what those figures were. However, your figures are entirely right when you examine adjusted EBITDA.
Is the audio coming through fine for everyone?
Yes, Jon, you're coming through loud and clear.
Nice work this quarter — quite striking, honestly. Can you go into a bit more detail regarding the SaaS offering and the app? Is it up and running? Are revenues coming in at this point? Has the FDA given its approval?
At the moment, talks are ongoing between us and the FDA, and that is genuinely everything I'm able to share at this point; we're keeping the process moving and hope to bring you all updates just as soon as possible.
Alright. So at this moment, it isn't bringing in any revenue?
As of now, no.
Also, could you give a bit more detail — you mentioned non-pharmaceutical programs regarding payments. Do you have anything else to add there?
Not really. Honestly, that mix of plasma plus our other business is essentially all we currently have when it comes to non-pharmaceutical business. There are targets we're pursuing, though it's a little early to talk about them right now; with luck, we'll be talking about them soon.
Your net cash is gradually climbing, reaching nearly $21 million this quarter. Are there any significant commitments remaining — I believe there's roughly $5 million or $6 million potentially tied to upcoming payments for Gamma's founders. Aside from that, are there any other obligations against that cash? And if there aren't, how do you plan to deploy some of it across the coming couple of years?
Pete, aside from the $6 million still owed to Gamma — which gets disbursed yearly on the following 3 anniversary dates in March — we have no cash payment commitments. So at this point, we're simply — we're retaining the cash, and that will remain our approach until a better purpose for those funds emerges. However, the company has never found itself in this kind of position — this favorable a position previously, with cash levels this elevated, and we'll keep expanding that reserve for either acquisitions or returning capital to shareholders or whatever you'd normally do with substantial cash balances.
Yes, yes. Also, I didn't notice that in the press release, and the Q isn't out yet, but did any share buybacks happen during the quarter?
None occurred, not in this quarter.
Appreciate that, Kevin. Thanks once more for being with us here today. We’re eager to share news about the progress we keep making when we speak again in the next quarter. Hope the remainder of your day treats everyone well.
Appreciate it. That brings today's teleconference and webcast to a close. At this point you're free to drop off the line, and we hope the rest of your day is great. Thanks for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Paysign, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Paysign, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.